Head and Neck Squamous Cell Carcinoma Market - Top Companies and Manufacturers

  • Report ID: 2839
  • Published Date: Jul 23, 2024
  • Report Format: PDF, PPT

Companies Dominating the Head and Neck Squamous Cell Carcinoma (HNSCC) Landscape

    • Immutep Limited
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Novartis AG
    • Fortress Biotech, Inc.
    • F. Hoffmann-La Roche Ltd
    • Eli Lilly and Company
    • Bristol Myers Squibb Company
    • AstraZeneca PLC
    • Pfizer Inc.
    • Boehringer Ingelheim International GmbH
    • Checkpoint Therapeutics, Inc.


In the News

  • Immutep Limited announced that it has completed the recruitment of patients having head and neck cancer and has safely dosed them for stage 2 of Part C of its Two ACTive Immunotherapies (TACTI-002) Phase II study trials.

  • Checkpoint Therapeutics, Inc. announced that it has expanded its partnership with Samsung Biologics Co., Ltd. for manufacturing the anti-PD-L1 antibody, cosibelimab on a commercial scale.


Author Credits:  Radhika Pawar


  • Report ID: 2839
  • Published Date: Jul 23, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of head and neck squamous cell carcinoma is assessed at USD 2.35 Billion.

The head and neck squamous cell carcinoma market size was over USD 2.18 Billion in 2023 and is anticipated to reach USD 6.51 Billion by the end of 2036, growing at around 8.8% CAGR during the forecast period i.e., between 2024-2036. Growing R&D and approvals for cancer drugs and treatment, escalating consumption of alcohol, and growing adoption of immune therapeutics are the major factors driving the market growth.

North America is poised to dominate majority industry share of about 52% by 2036, propelled by increasing frequency of head and neck cancer driven by surging ratio of alcohol, and tobacco consumption in people in the region.

Immutep Limited, Novartis AG, Fortress Biotech, Inc., F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bristol Myers Squibb Company, AstraZeneca PLC, Pfizer Inc., Boehringer Ingelheim International GmbH, Checkpoint Therapeutics, Inc.

In the year 2024, the industry size of head and neck squamous cell carcinoma is assessed at USD 2.35 Billion.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample